Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.
OBJECTIVE
To investigate the effects of vascular endothelial growth factor gene therapy on ischemic neuropathy in patients with critical limb ischemia.


METHODS
An open-label, dose-escalating trial. Patients with angiographically proven critical leg ischemia received injections of phVEGF(165) human plasmid in the muscles of the ischemic limb. Testing before treatment and at 3 and 6 months included (1) symptom severity score, (2) clinical examination score, and (3) electrophysiologic studies. Clinical and electrophysiologic examiners were masked to each other's findings.


METHODS
A tertiary care referral hospital and a major teaching affiliate of Tufts University School of Medicine, Boston, Mass.


RESULTS
Of 29 consecutive patients enrolled, 17 (19 limbs) completed the 6 months of study. Six patients had diabetes. Compared with baseline studies, treated patients had significant clinical improvements in the symptom score (P<.01), sensory examination score (P<.01), total examination score (P =.01), peroneal motor amplitude (P =.03), and quantitative vibration threshold (P =.04). Improvement in the vascular ankle-brachial index in treated legs (P<.01) corresponded to improvement in neuropathy in the same limb. Neurologic improvement was seen in 4 of 6 patients with diabetes who completed the study. No clinical, electrophysiologic, or vascular improvements were observed in untreated legs.


CONCLUSIONS
Ischemic neuropathy might be a reversible condition, and therapeutic angiogenesis might be an effective treatment. The presence of diabetes does not preclude a response to this therapy.
Simovic
D
D
St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135, USA.
Isner
J M
JM
Ropper
A H
AH
Pieczek
A
A
Weinberg
D H
DH
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D015331:Cohort Studies; D016638:Critical Illness / Q000628:therapy*; D004594:Electrophysiology; D016228:Endothelial Growth Factors / Q000235:genetics*; D005260:Female; D018628:Gene Dosage; D015870:Gene Expression; D015316:Genetic Therapy; D006801:Humans; D007511:Ischemia / Q000503:physiopathology / Q000628:therapy*; D007866:Leg / Q000294:innervation*; D008222:Lymphokines / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic; D010525:Peripheral Nerves / Q000098:blood supply* / Q000503:physiopathology; D011446:Prospective Studies; D012677:Sensation; D012720:Severity of Illness Index; D019076:Transgenes / Q000235:genetics; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors